Posted in | Nanobusiness

NIH-STTR Grant to Advance NeuroSigma’s Thin-Film Nitinol-Covered Neurovascular Stent

The National Institute of Neurological Disorders and Stroke (NINDS) has awarded a Phase I NIH-STTR grant to advance NeuroSigma’s thin-film nitinol (TFN)-covered stent for potential brain aneurysm treatment.

The sponsored research organization in this STTR grant is Mayo Clinic. The University of California, Los Angeles (UCLA) developed the TFN-covered stent technology. NeuroSigma’s majority-owned subsidiary, NSVascular is the exclusive global licensee of the technology through a deal signed with UCLA in 2011. NSVascular was formed in the same year by NeuroSigma.

Nitinol is an alloy of nickel and titanium with special properties. The superelastic alloy can be deformed and recovered to its original shape when exposed to body heat. Initially, NSVascular will concentrate on designing and marketing TFN-covered stents for use in endovascular applications, of which its first applications will be flow-diverting stents for treating intracranial aneurysms and stents for peripheral artery disease treatment.

The Phase I grant of NeuroSigma is roughly $680,000 in two tranches for a period of over one year, with the second tranche based on the fund availability and satisfactory development made utilizing the first tranche. The NINDS STTR scheme may offer follow-on Phase II fund of up to $3 million for further clinical studies. The primary objective of the scheme is the advancement and pre-clinical study of NeuroSigma's TFN-covered stent for potential brain aneurysm treatment.

The STTR grant’s Principal Investigator is NeuroSigma’s Director of Advanced Materials. David Johnson. He is widely recognized as a pioneer in the TFN fabrication. Drs. David Kallmes, Antonio De Salles and Colin Kealey are the co-investigators of the project. Dr. Kallmes is an interventional neuroradiologist, who will handle the pre-clinical studies that will be conducted at Mayo Clinic by his team. Dr. De Salles is the co-founder of NeuroSigma and serves as a Senior Medical Advisor for NeuroSigma and a Neurosurgery Professor at UCLA. Dr. De Salles is a Professor of Neurosurgery at UCLA, and co-founder and Senior Medical Advisor at NeuroSigma.

Source: http://www.neurosigma.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chai, Cameron. (2019, February 12). NIH-STTR Grant to Advance NeuroSigma’s Thin-Film Nitinol-Covered Neurovascular Stent. AZoNano. Retrieved on November 27, 2020 from https://www.azonano.com/news.aspx?newsID=24644.

  • MLA

    Chai, Cameron. "NIH-STTR Grant to Advance NeuroSigma’s Thin-Film Nitinol-Covered Neurovascular Stent". AZoNano. 27 November 2020. <https://www.azonano.com/news.aspx?newsID=24644>.

  • Chicago

    Chai, Cameron. "NIH-STTR Grant to Advance NeuroSigma’s Thin-Film Nitinol-Covered Neurovascular Stent". AZoNano. https://www.azonano.com/news.aspx?newsID=24644. (accessed November 27, 2020).

  • Harvard

    Chai, Cameron. 2019. NIH-STTR Grant to Advance NeuroSigma’s Thin-Film Nitinol-Covered Neurovascular Stent. AZoNano, viewed 27 November 2020, https://www.azonano.com/news.aspx?newsID=24644.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit